Associated tags: Therapy, NSCLC, IPF, Cancer, Ulcerative colitis, Lung cancer, South Korea, Idiopathic pulmonary fibrosis, Fibrosis, Pharmaceutical industry, Inflammation, Business development, EGFR
Locations: MASSACHUSETTS, SOUTH KOREA, UNITED STATES, NORTH AMERICA, ASIA PACIFIC, BOSTON, KOREA
Emory University,
CD4,
CD8,
Immunotherapy,
Lab,
Oncology,
Inflammation,
Patient,
Immunosuppression,
Neoplasm,
Research,
ATX,
Cancer,
Lung cancer,
Winship Cancer Institute,
Fibrosis,
Hematology,
Pharmaceutical industry As a member of the cancer immunology research program at Winship Cancer Institute of Emory University, Dr. Konen's research has shown that autotaxin has a direct impact on the body's immune response to tumors.
Key Points:
- As a member of the cancer immunology research program at Winship Cancer Institute of Emory University, Dr. Konen's research has shown that autotaxin has a direct impact on the body's immune response to tumors.
- The ongoing research collaboration is dedicated to investigating the potential benefits of combining BBT-877 with anti-PD-1 therapy as a treatment approach.
- "We are pleased to work with Bridge Biotherapeutics to explore indication expansion into NSCLC through a combination of BBT-877 with anti-PD-1 agent and potentially offer new hope to those patients."
- Together, the two entities will conduct preclinical studies to evaluate the therapeutic potential of BBT-877 in enhancing anti-tumor immunity.
LPA,
Microbiology,
Metabolism,
CD8,
LPAR,
LPAR5,
Lab,
Inflammation,
Research,
Immunology,
ATX,
Cancer,
University,
Fibrosis,
Schweizer SGU 1-6,
Vaccine The collaboration will focus on exploring the potential of BBT-877, a novel autotaxin (ATX) inhibitor, as an immuno-oncology treatment for cancer.
Key Points:
- The collaboration will focus on exploring the potential of BBT-877, a novel autotaxin (ATX) inhibitor, as an immuno-oncology treatment for cancer.
- "We are excited to collaborate with Dr. Torres's Lab to investigate the potential of BBT-877 as a novel immuno-oncology treatment," said James Lee, CEO of Bridge Biotherapeutics.
- Under the terms of the collaboration, Bridge Biotherapeutics will provide financial support and access to BBT-877, while Dr. Raul Torres's Lab will contribute its expertise in immunology and cancer biology.
- Together, the two entities will conduct preclinical studies to evaluate the therapeutic potential of BBT-877 in enhancing anti-tumor immunity.
Retrieved on:
Thursday, December 14, 2023
Survival,
American Lung Association,
Idiopathic pulmonary fibrosis,
Elasticity,
IPF,
Therapy,
Gestational sac,
CXCR4,
Patent,
Oxygen,
GPCR,
Signal,
Scar,
Diagnosis,
Fibrosis,
Communication,
KRW,
G protein-coupled receptor,
Pharmaceutical industry SEOUL, Korea and REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage international biopharmaceutical company, announces it enters into an out-licensing agreement with Bridge Biotherapeutics (KQ288330) for the CXCR4-LPA1 inhibitor combination method of treatment.
Key Points:
- SEOUL, Korea and REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage international biopharmaceutical company, announces it enters into an out-licensing agreement with Bridge Biotherapeutics (KQ288330) for the CXCR4-LPA1 inhibitor combination method of treatment.
- In collaboration with Bridge Biotherapeutics, GPCR will pursue joint development and commercialization of the combination therapy.
- Conducting a multinational phase 2a clinical trial of BBT-877, an autotaxin inhibitor for the treatment of IPF, Bridge Biotherapeutics has been accelerating development of its proprietary IPF pipeline.
- The target GPCRs are known to promote fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).
Drug development,
Therapy,
AUC,
Inflammation,
Cancer,
Biomarker,
Science,
Pulmonary fibrosis,
Thrombosis,
Fibrosis,
CXCL13,
CCL18,
Patient,
Physician,
Medicine,
MMP-7,
Idiopathic pulmonary fibrosis,
Disease,
Pharmaceutical industry SEONGNAM, South Korea and CAMBRIDGE, Mass., July 11, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for fibrosis, cancer and inflammation, announced that it has joined PROLIFIC, the Prognostic Lung Fibrosis Consortium, an organization devoted to boosting scientific exploration and drug development in pulmonary fibrosis.
Key Points:
- SEONGNAM, South Korea and CAMBRIDGE, Mass., July 11, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for fibrosis, cancer and inflammation, announced that it has joined PROLIFIC , the Prognostic Lung Fibrosis Consortium, an organization devoted to boosting scientific exploration and drug development in pulmonary fibrosis.
- PROLIFIC is a non-profit consortium of top-tier research institutions, academic medical centers, and pharmaceutical and biotech companies that are committed to developing treatments for pulmonary fibrosis.
- By joining PROLIFIC, Bridge Biotherapeutics will be able to collaborate with other pioneering companies in the area of pulmonary fibrosis.
- In addition to industry-wide advances, Bridge Biotherapeutics hopes to speed development of proprietary idiopathic pulmonary fibrosis pipeline and accelerate development of novel treatments for patients.
Oncology,
Health,
General Health,
Research,
Science,
Biotechnology,
Fibrosis,
Business development,
Cancer,
Idiopathic pulmonary fibrosis,
EGFR,
FDA,
Inflammation,
Lung cancer,
Pharmaceutical industry Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, will present an overview of its pipeline in multiple disease states on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston June 5-8.
Key Points:
- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, will present an overview of its pipeline in multiple disease states on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston June 5-8.
- This press release features multimedia.
- View the full release here: https://www.businesswire.com/news/home/20230602005303/en/
Pavel Printsev, Director of Business Development, will provide a overview of the company’s science and an introduction to its clinical-stage assets:
BBT-176 -- Fourth-generation EGFR TKIs for non-small cell lung cancer active against C797S resistance mutations, currently in a Phase I/II dose escalation study
BBT-877 -- Autotaxin inhibitor for idiopathic pulmonary fibrosis, currently in a Phase IIa trial
BBT-207 -- Fourth-generation EGFR TKIs for non-small cell lung cancer active against C797S resistance mutations, which recently received FDA clearance for a first-in-human Phase I/II
Mr. Printsev will also give an overview of Bridge Biotherapeutics’ newly acquired biosensing technology and its plans to commercialize these novel capabilities.
SEONGNAM, South Korea and CAMBRIDGE, Mass., May 29, 2023 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is scheduled to give a company presentation on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston, Massachusetts, between June 5 - 8, 2023.
Key Points:
- SEONGNAM, South Korea and CAMBRIDGE, Mass., May 29, 2023 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is scheduled to give a company presentation on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston, Massachusetts, between June 5 - 8, 2023.
- The company presentation is expected to include an introduction to the newly acquired biosensing technology and commercial prospects.
- "We are pleased to share the progress of clinical assets as well as new business activities through an in-person presentation at this year's BIO International conference, following last year's event.
- We look forward to advancing our novel research and development pipeline with a strong focus on oncology and pulmonology," stated Pavel Printsev, Director of Business Development of Bridge Biotherapeutics.
Retrieved on:
Wednesday, April 19, 2023
Survival rate,
DTC,
AACR,
Drug development,
Therapy,
Week,
Survival,
New Drug Application,
Cancer,
Lung cancer,
American Association for Cancer Research,
NSCLC,
Inflammation,
Ulcerative colitis,
Fibrosis,
Korea,
South Korea,
Patient,
EGFR,
Mouse,
Poster,
FDA,
IPF,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
IND,
TGI,
Idiopathic pulmonary fibrosis,
Food,
Pharmaceutical industry At last year's AACR annual meeting, the company disclosed initial preclinical data for BBT-207 and discussed the potency of the drug candidate against EGFR C797S double mutations inclusive of Del19/C797S (DC) and L858R/C797S (LC) as well as driver mutations including Del19 and L858R.
Key Points:
- At last year's AACR annual meeting, the company disclosed initial preclinical data for BBT-207 and discussed the potency of the drug candidate against EGFR C797S double mutations inclusive of Del19/C797S (DC) and L858R/C797S (LC) as well as driver mutations including Del19 and L858R.
- In this year's poster presentation, the company highlighted BBT-207's intracranial anti-tumor activity, as well as additional data showing the experimental drug's anti-tumor efficacy.
- Following last year's data disclosure, both in vitro and in vivo efficacy data included in this year's poster have shown that BBT-207 boasts robust anti-tumor efficacy.
- Bridge Biotherapeutics first released preclinical research data on BBT-207 at AACR last year.
Organization,
Fibrosis,
Business development,
SAN,
Drug discovery,
Biotechnology,
South Korea,
Large-cell lung carcinoma,
Partnership,
Inflammation,
Ulcerative colitis,
IPF,
EGFR,
Therapy,
Cancer,
Idiopathic pulmonary fibrosis,
NSCLC,
Korea,
Pharmaceutical industry SAN FRANCISCO and SEONGNAM, South Korea, Jan. 3, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and inflammation, announced that the company is presenting at Biotech Showcase™ 2023.
Key Points:
- SAN FRANCISCO and SEONGNAM, South Korea, Jan. 3, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and inflammation, announced that the company is presenting at Biotech Showcase™ 2023.
- "We are glad to be able to give an in-person corporate presentation at this year's Biotech Showcase.
- "We are delighted that Bridge Biotherapeutics will be joining us in San Francisco and presenting at Biotech Showcase this year," said Sara Demy, CEO of Demy-Colton.
- Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs including ulcerative colitis, fibrotic diseases, and cancers.
Data management,
Health,
Technology,
Networks,
Pharmaceutical,
Internet,
Biotechnology,
Medical specialties,
Medicine,
Clinical medicine,
Autoimmune diseases,
Abdominal pain,
Colitis,
Diarrhea,
RTT,
Ulcerative colitis,
Pellino,
Bridge Biotherapeutics,
Atomwise Atomwise and Bridge will rapidly cycle through the design and testing of potent small molecule compounds, evaluating billions of possibilities that will selectively inhibit Pellino proteins.
Key Points:
- Atomwise and Bridge will rapidly cycle through the design and testing of potent small molecule compounds, evaluating billions of possibilities that will selectively inhibit Pellino proteins.
- Bridge is a pioneer in Pellino therapies and leads the development of BBT-401, the first-in-class Pellino-1 peptide inhibitor, currently in Phase 2 for ulcerative colitis (UC) treatments.
- Our partnership with Atomwise will give us a competitive edge to build and expand an innovative first-in-class portfolio, upon our rich experience in Pellino-1 inhibitor development.
- Under the research collaboration agreement, Atomwise will receive upfront, milestone and royalty payments upon success for each research program.
